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illness in pediatrics worldwide. Most LRTIs in pediatrics are due to viral causes, yet conservative clinical
guidelines advise empiric antibiotic therapy because there is no reliable method to determine the etiology of
the illness. With the increasing threat of antibiotic resistance, efforts are underway to decrease the use of
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of relevant articles. Results: Included in this systematic review were two studies that met inclusion criteria. A
randomized, multi-center clinical trial with 337 participants demonstrated a statistically significant reduction
in the duration of antibiotic therapy, but an increase in the antibiotic prescription rate overall when applying
PCT-guided antibiotic therapy. A randomized, single-center clinical trial with 310 participants demonstrated a
statistically significant reduction in the duration of antibiotic therapy and antibiotic prescription rate when
PCT-guided antibiotic therapy was applied.
Conclusion: PCT-guided antibiotic therapy has been shown to reduce the duration of antibiotic therapy.
Furthermore, it is suggested that in less severe LRTI PCT-guided antibiotic therapy can reduce antibiotic
prescription rates in a pediatric population. More randomized control trials are needed to increase the
statistical power behind these findings. There was no evidence of increased risk of disease-specific adverse
events. At this time PCT-guided therapy is recommended to reduce the duration of antibiotic therapy.
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Abstract   
Background: Procalcitonin (PCT) is a marker for bacterial infection that can be used as a 
diagnostic tool to help distinguish viral from bacterial lower respiratory tract infections 
(LRTI). LRTI is a leading cause of illness in pediatrics worldwide. Most LRTIs in 
pediatrics are due to viral causes, yet conservative clinical guidelines advise empiric 
antibiotic therapy because there is no reliable method to determine the etiology of the 
illness. With the increasing threat of antibiotic resistance, efforts are underway to 
decrease the use of antibiotics. PCT-guided antibiotic therapy has shown a reduction in 
the use of antibiotics for adult LRTI. Can PCT-guided antibiotic treatment of LRTIs in a 
pediatric population reduce the antibiotic therapy duration rate or prescription rate with 
comparable outcomes to current therapy guidelines? 
 
Method: An exhaustive search was conducted using Medline-OVID, CINAHL, and Web 
of Science using the keywords: procalcitonin, antibiotic, pediatrics, and lower respiratory 
tract infection. A search on the NIH clinical trials site revealed that there are no trials 
currently registered relating to the use of PCT-guided antibiotic therapy in pediatrics with 
lower respiratory tract infections. GRADE was used to assess the quality of relevant 
articles. 
 
Results: Included in this systematic review were two studies that met inclusion criteria.  
A randomized, multi-center clinical trial with 337 participants demonstrated a statistically 
significant reduction in the duration of antibiotic therapy, but an increase in the antibiotic 
prescription rate overall when applying PCT-guided antibiotic therapy.  A randomized, 
single-center clinical trial with 310 participants demonstrated a statistically significant 
reduction in the duration of antibiotic therapy and antibiotic prescription rate when PCT-
guided antibiotic therapy was applied.  
 
Conclusion:  PCT-guided antibiotic therapy has been shown to reduce the duration of 
antibiotic therapy. Furthermore, it is suggested that in less severe LRTI PCT-guided 
antibiotic therapy can reduce antibiotic prescription rates in a pediatric population. More 
randomized control trials are needed to increase the statistical power behind these 
findings. There was no evidence of increased risk of disease-specific adverse events. At 
this time PCT-guided therapy is recommended to reduce the duration of antibiotic 
therapy.  
 
Keywords: Procalcitonin, Antibiotics, Pediatrics, Lower Respiratory Tract Infection, 
Pneumonia, human 
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The Utility of Procalcitonin-Guided Antibiotic Therapy in the Treatment of Lower 
Respiratory Tract Infections for Reducing Antibiotic Prescription Rate and 
Therapy Duration in Pediatrics 
BACKGROUND 
 Lower respiratory tract infections (LRTI), including pneumonia, are one of the 
leading causes of hospitalization and death in children worldwide. In 2010 almost 15 
million children ages 5 and under were hospitalized with severe pneumonia, resulting in 
over 250 000 deaths.1 The etiology of an LRTI is often difficult to ascertain due to time-
consuming cultures with poor sensitivity and specificity, along with a high frequency of 
contamination.2 As a result, diagnosis is often based on clinical signs and symptoms such 
as fever >38.5°C, chest recession, and a raised respiratory rate.3,4 The etiology of an 
LRTI in children has primarily been found to be viral,6 especially in children under the 
age of 2 where respiratory syncytial virus is largely the culprit of LRTIs.7,8 It is estimated 
that 1/3 of all LRTIs are caused by mixed viral and bacterial agents.5 As a child ages, 
bacterial etiology of an LRTI becomes more common, with Streptococcus pneumoniae 
being the leading bacterial agent causing LRTI through all ages.9 As a result of possible 
mixed etiology and a lack of reliable diagnostic testing to differentiate a viral and 
bacterial LRTI, most guidelines indicate treating empirically with antibiotics.3-5  This has 
lead to rampant inappropriate treatment of viral infections with antibiotics. In accordance, 
the ubiquitous use of antibiotics has lead to antibiotic resistant bacteria one of which is 
Streptococcus pneumonia,10 the same strain that causes most community-acquired 
pneumonia (CAP).9  
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To put this problem into perspective, the CDC conservatively estimates that 
within the United States, “at least 2 million people become infected with bacteria that are 
resistant to antibiotics and at least 23 000 people die each year as a direct result of these 
infections.”11 The severity of this problem has not gone unrecognized by the federal 
government. The 2016 Presidential Budget Proposal has allocated $1.2 billion for 
combating antibiotic-resistant bacteria. Per the National Strategy for Combating 
Antibiotic-Resistant Bacteria, this money will go towards antibiotic stewardship 
particularly for the “development and dissemination of licensed point-of-need diagnostic 
tests that distinguish between bacterial and viral infections in 20 minutes or less.”12 The 
idealized ‘point-of need diagnostic test’ may already be in existence in the form of a 
qualitative point-of-need procalcitonin (PCT) test. 
Among the commonly used biomarkers of bacterial infection, including white 
blood cell (WBC) count and C-reactive protein (CRP), PCT has risen above and beyond 
the rest due to its high sensitivity for bacterial infection.2 PCT is an amino acid peptide 
that is undetectable in a healthy individual but is noted to rapidly elevate in patients 
exposed to bacterial endotoxins and, due to a long half-life, remains elevated 12-48 hours 
after initial exposure.13-15 It has been found that a PCT level less than 0.25μg/L has a high 
negative predictive value in excluding bacterial disease in the setting of CAP.16 There are 
currently several commercially available PCT assay tests on the market including one 
qualitative point-of-need test made by Brahms commonly used to detect PCT level.17 As 
a result many studies have been conducted utilizing PCT level to dictate when antibiotics 
should be delivered. Of particular interest is a Cochrane systematic review titled 
Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. It 
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is based on an adult population that has shown “The use of [PCT] to guide initiation and 
duration of antibiotic treatment in patients with [acute respiratory tract infection] was not 
associated with higher mortality rates or treatment failure, but significantly reduced 
antibiotic consumption.” Given the robust findings of this systematic review,18 it seems 
likely that the point-of-need PCT test will surely permeate throughout many clinical 
settings as a tool for reducing the use of antibiotics.  Children are a likely future target for 
PCT testing as they, more than adults, suffer from viral LRTI, rather than bacterial. 6 
Thus, great headway could be made in the name of antibiotic stewardship on this front.  
Can PCT-guided antibiotic treatment of LRTIs in a pediatric population reduce the 
antibiotic prescription rate or therapy duration with comparable outcomes to current 
therapy guidelines? 
METHODS 
 A comprehensive search of accessible medical databases was conducted using 
Medline-Ovid, Web of Science, and CINAHL using the keywords procalcitonin, 
pediatric, lower respiratory tract infections, and antibiotic. The search was then narrowed 
to include only English language articles. Studies chosen included prospective 
randomized clinical trials (RCT) that evaluated for antibiotic rate and duration in the 
application of PCT-guided antibiotic therapy in the treatment of LRTI in pediatrics as 
compared to standard guidelines. The included studies were evaluated for bias and 
assessed using the Grading of Recommendations, Assessment, Development, and 
Evaluation (GRADE).19 No relevant trials in accord with the particular parameters of this 
review are registered with the National Institute of Health (NIH) at this time. 
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RESULTS 
The initial database search unveiled 22 articles, two of which met inclusion 
criteria. Both studies20,21 are randomized clinical control trials containing primary data on 
human subjects. The characteristics of both studies are summarized in Table 1. 
Baer et al 
This randomized, multi-center, clinical trial20 investigated the application of a 
PCT algorithm for the determination of antibiotic therapy in pediatric patients presenting 
with an LRTI as compared to standard clinical care guidelines. The primary outcome 
assessed was the rate of antibiotic prescriptions. While the secondary outcomes assessed 
were the duration of antibiotic treatment, antibiotic side effects, hospitalization rates, and 
serious adverse events (SAE) including disease specific failure. Additionally subjective 
information was collected in the form of a diary on the patient’s perceived impairment of 
daily activities.20 
Children presenting with an LRTI to one of two emergency departments (ED) in 
Switzerland were randomly assigned to either the PCT-guided group or the standard 
clinical care group (control group). Physicians treating with PCT guidance were 
instructed to prescribe antibiotics in accordance with the likelihood of a bacterial 
infection as indicated by the following PCT levels: definitely  (> 0.5 μg/L), probably  
(0.26 - 0.5 μg/L), probably not (0.1 - 0.25 μg/L), definitely not (< 0.1 μg/L).  PCT levels 
were taken on days 1, 3, and 5. On Day 5, PCT levels were measured and if >1 μg/L then 
antibiotic therapy was continued for 7 days; if between 0.51-1 μg/L, then therapy 
continued for 5 days; if between 0.26-0.5 μg/L then therapy continued for 3 days; and if ≤ 
0.25 μg/L then antibiotic therapy was stopped. Moreover, if the patient’s PCT levels fell 
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to less than 90% of the initial PCT (in the case that the initial PCT > 10 μg/L) antibiotics 
were also discontinued. If a physician at anytime felt as though the child had severe co-
morbidities, hemodynamic or respiratory instability, or an emerging need for the ICU 
they could be given antibiotics regardless of their PCT level. The control group was 
treated with antibiotics per the physician assessment and clinical guidelines for a duration 
of 7 to 10 days for uncomplicated CAP and 14 or more days for complicated CAP. 20 
Inclusion criteria consisted of only patients between the ages of 1 month and 18 
years presenting with acute LRTI.  Acute LRTI included non-CAP (bronchitis and 
bronchiolitis) and CAP. All patients had a fever of at least 38°C and at least one sign and 
one symptom of LRTI. Possible signs included tachypnea, dyspnea, wheezing, late 
inspiratory crackles, bronchial breathing, and pleural rub. Possible symptoms included 
cough, sputum production, pleuritic pain, and poor feeding. CAP was confirmed by new 
or increasing alveolar infiltrate found on chest radiograph. All patients unable to give 
written consent and/or had language barriers were excluded from the trial. Furthermore, 
all patients with severe immune depression, cystic fibrosis, acute croup, and a hospital 
stay within the previous 14 days or with another serious infection were excluded from the 
trial. Follow up consisted of a phone call from a pediatrician blinded to patient allocation 
14 days after randomization. Full clinical recovery was determined at that point. Follow 
up was incomplete for 2% of patients, all of who were within the control group. 20 
From a total of 946 eligible LRTI patients initially presented, 50% (473) were 
chosen for evaluation of which 339 met inclusion criteria with 2 withdrawing consent 
after randomization. Patients were randomized using variable block randomization with 
stratification for the two EDs and for the type of LRTI. Ultimately 169 (107 with CAP 
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and 62 with non-CAP) were enrolled in the control group and 168 (108 with CAP and 60 
with non-CAP) were in the PCT-guided group. Baseline patient characteristics were 
similar in both treatment groups. 20 
Antibiotic prescription rates were found to unexpectedly, and without much 
statistical significance, increase with PCT guidance. The duration of antibiotic therapy 
however, was decreased as expected. There were 62% from the PCT-guided group and 
56% of the control group that were given antibiotics within 14 days of randomization, 
with a calculated difference of 6% (95% CI -5%, 16%; P=0.359). While the mean 
duration of antibiotic therapy was 4.5 days in the PCT-guided group, it was 6.3 days for 
the control group amounting to a statistically significant mean difference of -1.8 days 
(95% CI -3.1, -0.5; P = 0.039). Antibiotic side effects were not significantly different 
between both groups, at 39% and 38% for PCT-guided and the control group 
respectively, the difference being 1% (95% CI -10, 12). Likewise, the rate of adverse 
events including complications of LRTI or disease specific failure was not significantly 
different at 23% and 20% for the PCT-guided group and the control group respectively, 
with a rate difference of 2% (95% CI -6, 11). There were 62% of the PCT-guided group 
and 60% of the control group who were hospitalized with 2% difference (95% CI -8,12). 
Of the 79% of patients who returned their diaries, the study investigators did not find any 
significant difference in the impairment of daily activities between the two groups. 20 
The authors discussed limitations of this study, including an acknowledgement 
that “pediatricians in Switzerland have a low rate of prescribing antibiotics in general.” 
Thus, a possible reasoning for the failure of PCT guidance to reduce the antibiotic 
prescription rate within their study. They also felt that the PCT cut-off levels used to 
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guide successful antibiotic initiation in LRTI in adults may have been too low in children 
especially for those with non-CAP LRTI. Authors of this study suggest that future 
research be aimed at determining the ideal PCT cut-off value for pediatric patients with 
LRTI for purposes of initiating or withholding antibiotic therapy. 20 
Esposito et al 
 This prospective, randomized, single-center control trial21 studied the utility of a 
PCT cut-off value to guide antibiotic therapy in pediatrics hospitalized with CAP as 
compared to the standardized clinical guidelines recommended by the Italian Society of 
Pediatrics. The primary outcome studied was the comparative rate of antibiotic 
prescriptions; whereas the secondary outcomes were the duration of antibiotic therapy, 
the rate of antibiotic side effects, and the return of LRTI symptoms requiring antibiotic 
therapy. 21 
 Eligibility criteria in this study21 centered on all children between the ages of 1 
month and 14 years who were hospitalized at the Department of Maternal and Pediatric 
Sciences at the University of Milan with certain clinical signs and symptoms. The signs 
and symptoms indicated included: history of fever, cough, tachypnea, dyspnea and 
respiratory distress, breathing with grunting or wheezing sounds with rales, and having 
confirmed radiographic findings on chest x-ray including pulmonary infiltrate or 
segmental or lobar consolidation. Of the 419 eligible patients, 100 were excluded because 
of complications such as pleural effusion, empyema, lung necrosis, pneumatocele, 
antibiotics taken within the past 10 days prior to admission, chronic disease, severe 
malnutrition, and other concurrent infections. The remaining 319 patients were allocated 
to treatment groups by computer-generated randomization and sealed envelope. Of the 
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319 patients randomized, 9 withdrew consent; leaving 155 in both the PCT-guided group 
and the control group. Baseline characteristics were balanced across both groups.21 
 The PCT algorithm applied to the PCT-guided group had very strict parameters. 
Both group participants had their PCT levels taken within 6 hours of admittance. While 
the control group all went on to receive antibiotics for no less than 7 days, the PCT-
guided group were only given antibiotics if their initial PCT level was greater than or 
equal to 0.25 μg/L. All patients’ PCT levels were monitored every other day until 
discharge and at the follow up visits, Day 14 and 28 after admission. If at any point an 
individual’s PCT levels in the PCT-guided group dropped below the 0.25 μg/L cut-off 
level, the antibiotics were discontinued. Likewise, if PCT levels rose above 0.25 μg/L 
patients were given antibiotics. If the physician felt that an untreated child showed no 
reduction or worsening clinical signs or symptoms at any time, antibiotics were given 
regardless of PCT level. 21 
 Overall, there was a statistically significant decrease in antibiotic rate and 
exposure in the PCT-guided group as compared to the control group (p < 0.05). Of the 
PCT-guided group, 14% were able to avoid antibiotics altogether, leaving 86% who took 
antibiotics. This was compared to the baseline of the control group, in which 100% took 
antibiotics (p < 0.05). Among the children in the PCT group, 1.5% discontinued 
antibiotics after 2 days, 4.6% after 4 days, 37.4% after 6 days, 46.6% after 8 days and 
only 11.5% received antibiotics beyond 10 days. Three of the patients who had 
discontinued antibiotics in the PCT-guided group went on to see a secondary spike in 
PCT level ≥ 0.25μg/L, resulting in a resumption of antibiotics until day 10, at which point 
symptoms resolved and PCT levels had dropped below 0.25μg/L. The control group saw 
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that 100% of patients received antibiotics for no less than 7 days, 82.6% for 10 days, 
25.2% for 12 days and 13.5% for 14 days. Within the PCT-guided and control group, 
0.6% and 3.9% respectively returned 2 to 3 weeks after discharge for worsening 
respiratory symptoms; all of who were considered cured 28 days after admission. This 
study found significantly more antibiotic-related adverse events in the control group 
versus the PCT-guided group at a rate of 25.2% and 3.9% (p <0.05) respectively. 21 
 Authors cited the small sample size to be a limitation as well as the fact that all of 
the patients were hospitalized with uncomplicated CAP. It was acknowledged that this 
study poorly represented children with a more severe disease particularly those with 
bacterial CAP resistant to commonly used antibiotics and children being treated in an 
outpatient setting. Further study on the safety of utilizing a PCT-based algorithm to treat 
CAP was recommended.21 
DISCUSSION 
In the end, both trials 20,21 adequately answered the clinical question: can PCT-
guided antibiotic treatment of LRTIs in pediatric populations reduce the antibiotic 
prescription rate or therapy duration with comparable outcomes to current therapy 
guidelines? PCT guidance can reduce antibiotic prescription duration; but only in certain 
situations does it appear to reduce the antibiotic prescription rate. Both trials20,21 show 
statistically significant evidence that antibiotic therapy duration can be reduced with the 
application of a PCT algorithm (RR of 0.68 and 0.48, for the Baer et al and Esposito et al 
trial respectively, see Table II). Yet the trials differed in regard to the effect PCT-guided 
therapy has on the rate of antibiotic initiation. The Esposito et al trial21 found that PCT-
guided therapy greatly reduces the antibiotic initiation rate (RR of 0.85) while the Baer et 
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al trial20 found that PCT guidance actually increases the antibiotic prescription rate as 
compared to the control group (RR of 1.13). The mixed findings could be due to a 
multitude of variables, including differences between the two study populations, standard 
practice guidelines and regional clinician preferences. 
Contradictory outcomes of antibiotic prescription rates can be attributable to 
differences in the average level of patient illness between the two studies.  For example, 
the average study participant in the Esposito et al trial21 had a PCT level of 1.8ug/L while 
the average PCT level in the CAP group in the Baer et al trial20 was 4.5ug/L, despite 
using the same PCT assays.20 This indicates that the study population within the Esposito 
et al trial was perhaps less ill than the CAP patients within the Baer et al trial. Which 
could have contributed to the relative success of the Esposito et al trial in reducing 
antibiotic prescription as compared to the Baer et al trial. 20,21 
This same phenomenon was appreciated in the adult trials as summarized in the 
Cochrane systematic review,18 where they found large differences between the rates of 
antibiotic prescription in the PCT group for different clinical settings. For example, the 
rate of antibiotic prescription in the PCT group while in a primary care office was 23%, 
in the emergency department it was 73%, and in the ICU it was 100%. Assuming that the 
severity of illness correlates with clinical setting (ie, the ICU treats more severe illness 
than primary care), there is an obvious trend within the PCT group towards an increased 
antibiotic prescription rate in the more severely ill.18 
A similar pattern was revealed in the breakdown of the Baer et al trial21 into non-
CAP and CAP groups, with the non-CAP group being less ill than the CAP group. Within 
the Baer et al PCT-guided group, 45% of the non-CAP patients received an antibiotic 
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prescription while 71% of patients in the CAP group received antibiotics. Severity of 
illness appears to play as important of a roll in children as is it does in adults. The author 
of the Cochrane systematic review18 concluded that for “patients at low risk for severe 
bacterial infection, a [PCT] algorithm is used to determine whether antibiotics should be 
initiated at all; in higher risk patients [PCT] was mainly used to determine when 
treatment could be safely discontinued.”18 The results of the Esposito et al21 and Baer et 
al trials20 indicate that this conclusion may hold true for both children and adults alike. 
Thus, in exploring a possible cause for the difference in outcome between the two 
studies,20,21 an answer for the clinical question may have been clarified.  
Another likely cause of the differing outcomes between the two trials, 20,21 could 
be the largely different approaches taken with the control groups. The Esposito et al 
study21 gave 100% of control patients antibiotics while the Baer et al trial20 gave 56% of 
the control patients antibiotics. Interestingly, the Esposito et al PCT-guided group 
reduced antibiotic prescription rates to levels comparable to the Baer et al20 control group. 
The Baer et al trial, as discussed earlier, was conducted in Switzerland, where antibiotic 
prescription rates tend to be lower than that the rest of Europe or the United States. 18,20 
Perhaps explaining why PCT guidance had not had the same comparative reduction in 
antibiotic prescriptions rates as it had in other parts of the world such as Italy where the 
Esposito et al trial was held.21 
To summarize, the RCTs20,21 answered the clinical question, confirming that a 
PCT algorithm can reduce the antibiotic duration and also reduce the antibiotic initiation 
rate in cases of less severe illness. This review further went on to discuss the regional 
differences in LRTI clinical guidelines. In doing so, the review highlighted a possible 
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tendency for more stringent clinical guidelines to reduce antibiotic initiation rates equally 
as well as PCT-guided protocol. 
Both trials20,21 were found to have a few shared limitations. First, due to the nature 
of the study neither trial was able to blind the physician. The physician was required to 
know treatment allocation in order to follow correct treatment protocol. Attempts could 
have been made at blinding the patient with a placebo yet there is little to suggest that a 
patient’s PCT level would change as a result.  Second and most importantly, neither trial 
reported a rate of adherence to the PCT algorithm. The Baer et al20 trial advised 
physicians to overrule the PCT algorithm in cases where the patient had a “life-
threatening infection”. Likewise, the Esposito et al trial21 stated that “in the case of severe 
clinical deterioration and regardless of their PCT levels, children in both groups could be 
treated with antibiotics or their treatment could be modified on the basis of their 
pediatrician’s judgment.” Lack of accountability for changes in treatment protocol not 
only risks the significance of the results but also allows for the influence of physician 
bias. The third shared limitation of both studies20,21 is the relatively small sample size of 
either trial.    
Both trials20,21 had their own unique limitations. The Baer et al trial20 included 
patients who had recently taken antibiotics prior to initiation, potentially compromising 
the initial PCT level and the outcomes relating to antibiotic initiation and duration. The 
Esposito et al trial,21 on the other hand, was limited by allocation bias. Although a 
computer randomized treatment protocol, the delivery of the selected treatment plan was 
by sealed, unnumbered envelope. This provided the physician with the potential to 
change the order of treatment allocation. Furthermore, the Esposito et al trial studied only 
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hospitalized children with uncomplicated CAP. Therefore, it poorly represented patients 
with severe disease or treatment in an outpatient setting.  
Based on the GRADE criteria,19 the combined quality of evidence of the two 
studies reviewed is moderate. Further randomized clinical control trials with larger 
sample sizes are needed to increase the statistical power behind these findings 
particularly in the varying clinical settings. Additionally, research into the optimal PCT 
cut-off levels in children with LRTI is needed in order to fully minimize antibiotic 
prescription rates within this population.  
CONCLUSION 
 With every antibiotic prescription written, the risk of antibiotic resistance 
increases. Point-of-need PCT testing is trending toward becoming the tool of the future to 
differentiate between viral and bacterial LRTI. Studies on adult patients have shown a 
reduction in antibiotic prescription rates and duration of therapy with the application of 
PCT-guided antibiotic therapy. Likewise, the evidence presented in this review indicates 
that the use of a PCT-guided algorithm in children can reduce the duration of antibiotic 
therapy and it can reduce the antibiotic prescription rate in cases of low acuity LRTI.  
There is a substantial and universal benefit to society and individuals in the 
reduction of antibiotic use. It is morally imperative that efforts be made in this regard. 
For the purpose of reducing the duration of antibiotic therapy in all clinical settings, the 
benefit of implementing PCT-guided therapy as a standard of practice outweighs any 
risks. Thus, as the point-of-need PCT test becomes more available, its use is 
recommended in guiding antibiotic therapy in pediatrics presenting with LRTI. Until that 
time however, stricter clinical guidelines dictating antibiotic use should be followed.  
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Table I. Characteristics of Reviewed Studies 
 
  Baer et al20 Esposito et al21 
Methods 
Randomized Clinical Trial, multi-center, 2 emergency 
departments in Switzerland. 
Computer generated list with web-based patient allocations. 
Randomized Clinical Trial, single-center, Department of 
Maternal and Pediatric Sciences at the University of Milan, 
Milan, Italy. 
Computer generated list with sealed envelope allocation. 
Participants 
Inclusion Criteria: Children Age >1 month to <18 years 
presenting with Acute LRTIa to the ED regardless of AB 
treatment history. Temperature ≥ 38°C. 
 
Exclusion Criteria: unable to get written consent or language 
barriers, severe Immune suppression,b cystic fibrosis, acute 
croup, hospital stay within previous 14 days or other severe 
infection.  
 
Included in this analysis: 337 out of 339 randomized patients: 
2 post randomization exclusions (2 withdrew consent) 
Inclusion Criteria: Children Age >1 month to < 14 years 
hospitalized with CAPc confirmed with CXRd. 
 
 
Exclusion Criteria: Complications such as pleural effusion, 
empyema, lung necrosis, pneumatocele. AB taken within the 
past 10 days  prior to admission. Chronic diseasee, severe 
malnutrition, other concurrent infections. 
 
Included in this analysis: 310 out of 319 randomized patients: 
9 post randomization exclusions (9 withdrew consent) 
Interventions 
Guiding antibiotic decisions in acute LRTI patients with 
repeated PCT measurements. 
 
Algorithm used for antibiotic therapy: 
Initiation: AB treatment likelihood at admission per PCT 
levels: 
Definitely  ( > 0.5μg/L) 
Probably  (0.26 - 0.5μg/L) 
Probably not (0.1 - 0.25μg/L) 
Definitely not (< 0.1μg/L) 
Continuation of AB on day 5 of treatment if PCT: 
> 1 μg/L : 7 days 
0.51 - 1 μg/L : 5 days 
0.26 -0.5 μg/L : 3 days 
≤0.25 μg/L: no antibiotic 
Discontinue:  when the patient stabilized and when PCT < 
0.25μg/L or when PCT levels fell to less than 90% of the initial 
PCT in the case that the initial PCT > 10μg/L. 
Exceptions to algorithm: severe co-morbidity, hemodynamic 
or respiratory instability, or emerging ICU need. 
Monitor: clinical assessment and PCT taken at day 1, 3 and 5 
Control: AB treatment was initiated based on physician 
assessment and clinical guidelines for a duration of 7-10 days 
for uncomplicated CAP and 14 or more days for complicated 
CAP. 
Guiding antibiotic decisions in CAP patients with repeated 
PCT measurements. 
 
Algorithm used for antibiotic therapy:  
Initiation: AB treatment at admission if PCT ≥ 0.25 μg/L   
AB were given to untreated children if their PCT levels 
increased to ≥ 0.25μg/L.  
Discontinue: When PCT levels dropped below 0.25μg/L.  
Exceptions to algorithm: Untreated children showing no 
clinical reduction in signs or symptoms or with clinical 
deterioration were given AB regardless of PCT level. 
Monitor: PCT levels taken within 6h of admission and every 
other day until discharge and at both follow up visits. 
Control: All patients received AB per the Italian Society of 
Pediatrics (SIP) guidelines. Antibiotic therapy was given 
between 7-14 days depending on severity. 
Outcomes 
Antibiotic prescription rate within 14 days of randomization  
Duration of antibiotic treatment, days 
Antibiotic Side Effects 
Duration of Antibiotic Side Effect, days 
Hospitalization 
Duration of hospitalization 
Safety (complications of LRTI)  
Antibiotic prescription rate 
Duration of antibiotic treatment 
Antibiotic Side Effects  
Reoccurrence of symptoms at day 28 
Duration of hospitalization 
Notes 
Funding: The division of infectious Diseases and Vaccines, 
University Children’s Hospital, Basel, Switzerland 
Follow up: At 14d from randomization, phone call from 
pediatrician blinded to treatment allocation. 
Registration: ISRCTN17057980 
Funding: Unknown 
Follow up: 14 ±2d and 28±3d post admission. Blinded 
pediatrician 
Registration: none 
 
aLRTI = Non-CAP (bronchitis, bronchiolitis) or CAP. CAP = LRTI w/new or increasing alveolar infiltrate on CXR. 
 Acute LRTI diagnosis: Fever ≥ 38°C + at least one sign and one symptom for less than 14 days.  
Signs: tachypnea, dyspnea, wheezing, late inspiratory crackles, bronchial breathing, pleural rub.  
Symptoms: cough, sputum production, pleuritic pain, poor feeding.  
bImmune suppressed = HIV infection with a CD4 count <15% of normal age specific counts, immunosuppressive treatments, neutropenia. 
cCAP w/clinical S&S: History of fever, cough, tachypnea, dyspnea and respiratory distress, breathing with grunting or wheezing sounds with rales.  
dIncluding: pulmonary infiltrate, segmental/lobar consolidation. 
eanatomic abnormality of the respiratory tract, immunologic deficits, progressing neurological conditions, psychomotor retardation, congenital heart 
disease, hemoglobinopathy   
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Table II. GRADE Evidence Profile: Quality Assessment and Summary of Findings 
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Table III. Summary of Biases 
 
 
 
